The latest medical insurance regulations for dasatinib in 2024

Dasatinib (Dasatinib) is an ATP competitive inhibitor of BCR-ABL, ephrin (EPH), c-Kit, PDGFRβ and Src family kinases. It has been approved by the US Food and Drug Administration (FDA) for the treatment of adult chronic myelogenous leukemia (CML) and Ph+ acute lymphoblastic leukemia (ALL). Preclinical studies have shown that dasatinib has certain efficacy in a variety of tumor types, including colorectal cancer.

Dasatinib, as an innovative drug targeting specific leukemias, has recently received new adjustments in medical insurance policies. According to the latest medical insurance regulations, dasatinib has been included in the national medical insurance drug catalog, which means that patients can enjoy a certain degree of cost reimbursement when purchasing the drug, effectively reducing the financial burden on patients. This medical insurance adjustment is aimed at ensuring that more patients who need dasatinib treatment can receive timely and effective treatment. Coverage by medical insurance not only lowers the threshold for drug accessibility, but also improves patients’ quality of life and prognosis.

The original drug dasatinib, which is currently on the market in China and has been included in medical insurance, may cost around RMB 10,000 per box. Eligible leukemia patients can enjoy a certain proportion of cost reimbursement according to local medical insurance policies when using dasatinib. This will undoubtedly bring good news to patients who have relied on this drug for a long time and can relieve stress when facing high medical expenses. In addition, the medical insurance policy also encourages medical institutions and doctors to give priority to the use of drugs in the medical insurance catalog where appropriate to ensure that patients can obtain high-quality treatment at a lower price.